INTRODUCTION
Hepatic fibrosis is the outcome of chronic liver injury in response to various etiologies. It is characterized by excess accumulation of abnormal extracellular matrix (ECM) and disruption of hepatic architecture. 1, 2 During liver fibrosis, ECM is converted from a collagen IV/VI-rich matrix to a collagen I/III-rich one, resulting in liver stiffness and distortion of the sinusoidal architecture. Long-term fibrosis leads to cirrhosis and subsequent liver dysfunction and hepatocellular carcinoma (HCC). 3 Activation of hepatic stellate cells (HSCs) plays a critical role in liver fibrosis and is characterized by the conversion from vitamin A-storing cell into myofibroblast that expresses excess profibrogenic genes, such as alpha-smooth muscle actin (a-SMA), collagen type I alpha 1 chain (Col1a1), collagen type I alpha 2 chain (Col1a2), tissue inhibitor of metalloproteinase 1 (Timp1), and fibronectin 1 (Fn1). a-SMA is a marker for activated HSCs, and it also enhances the contraction force of HSCs by incorporating into stress fibers. 4, 5 The contractility of HSCs leads to increased liver stiffness and hepatic sinusoidal vasoconstriction, two key events that cause liver complications, like portal hypertension. 6, 7 Identification of molecules that regulate HSC activation and liver fibrogenesis may provide novel therapeutic targets. To date, whether microRNAs (miRNAs) have a role in these processes remains poorly understood. miR-125b is frequently dysregulated in human diseases, especially in cancers. Recent reports have shown that miR-125b is also implicated in different liver diseases. For instance, miR-125b attenuates paracetamol-and FAS-induced toxicity in hepatocytes and prevents acute liver failure (ALF) by directly targeting kelch-like ECH-associated protein 1 (Keap1); 8 upregulation of miR-125b protects female mice from non-alcoholic fatty liver disease through repressing lipid accumulation in hepatocytes, 9 and downregulation of miR-125b in cholangiocyte enhances proliferation of cholangiocytes during bile duct ligation (BDL)-induced cholestatic liver injury. 10 In addition, miR-125b promotes apoptosis and inhibits proliferation and metastasis of HCC cells. 11, 12 Some studies have also revealed that miR-125b level is increased in mouse fibrotic livers 13 and in the serum of patients with liver fibrosis. 14 However, the function and its underlying mechanism of miR-125b in HSC activation and liver fibrosis remain unknown.
Here, we showed that miR-125b was significantly upregulated in murine activated HSCs, but not in hepatocytes, during liver fibrogenesis. Inhibition of miR-125b dramatically suppressed the activation of murine HSCs in vitro and attenuated hepatic fibrosis in vivo. Moreover, miR-125b enhanced the activity of RhoA by directly targeting StAR-related lipid transfer (START) domain containing 13 (Stard13) expression, consequently increasing the level of a-SMA and the contractile ability of HSCs. This study reveals a promotive function of miR-125b in HSC activation and hepatic fibrosis, and this may be beneficial for developing miR-125b-based therapy for liver fibrosis. To assess the function of miR-125b in liver fibrosis, we first evaluated by qRT-PCR the expression of miR-125b in fibrotic liver tissues. Compared with normal livers, the level of miR-125b was significantly increased in human fibrotic livers ( Figure 1A) , and also in mouse fibrotic livers ( Figure 1B ) that were derived from the mice with treatment of carbo tetrachloride (CCl 4 ) or BDL (Figures S1A-S1D ), two widely used models of experimental liver fibrosis. To clarify which cell type displayed miR-125b The level of miR-125b was increased in fibrotic livers. Samples were collected from human (A) and CCl 4 -or BDL-treated mice (B). (C and D) miR-125b was upregulated in the activated HSCs, but not in hepatocytes, isolated from the fibrotic livers of CCl 4 -or BDL-treated mice. Mouse primary HSCs (C) and hepatocytes (D) were isolated from normal or fibrotic livers. (A-D) miR-125b was detected by qRT-PCR analysis, and the mean value of miR-125b expression in the control group was set to 1. (E) Schematic diagram of the lentiviral vector of miR-125b-sponge and its control. Control lentivirus (Ctrl) carried mCherry reporter gene driven by the cytomegalovirus (CMV) promoter. miR-125b-sponge (sponge) had the same structure as the control lentivirus except that six tandem repeats of the miR-125b binding sequence were inserted immediately after the stop codon of the mCherry coding sequence. The consensus sequence of the miR-125b binding site in the sponge is shown. (F) An illustration showing experimental procedures of antagonizing endogenous miR-125b with lentiviral sponge in CCl 4 -treated mice. Liver fibrosis was induced in mice by an intraperitoneal injection of CCl 4 twice weekly for 4 weeks. Lentivirus with the miR-125b-sponge or control lentivirus was injected through the tail vein on the fifth and seventh days after the first administration of CCl 4 . Mouse livers were collected and subjected to immunohistochemistry analysis or hydroxyproline assay 3 weeks after the last injection of lentiviruses. (G and H) Antagonizing endogenous miR-125b alleviated liver fibrosis in vivo. Expression of a-SMA and deposition of collagen were detected by immunohistochemistry staining and Sirius Red staining (G), respectively. Hydroxyproline content of livers was determined by the Hydroxyproline Colorimetric Assay kit (H). Scale bar, 250 mm. Data are presented as mean ± SEM in (A)-(D), (G), and (H). *p < 0.05; **p < 0.01. ns, not significant. dysregulation during fibrosis, we analyzed miR-125b level in primary hepatocytes and HSCs isolated from murine livers. Compared with primary HSCs from normal livers, those from the fibrotic livers of CCl 4 -or BDL-treated mice showed a significant upregulation in miR-125b ( Figure 1C) , a-SMA, and type I collagen (Figures S2A and S2B) expression. However, hepatocytes from fibrotic and normal livers exhibited similar miR-125b levels ( Figure 1D ). These data suggest that increase of miR-125b in HSCs may contribute to liver fibrosis.
We then explored whether antagonism of miR-125b could block liver fibrosis in vivo, using "sponge" strategy 15 to sequester cellular endogenous miR-125b. The miR-125b-sponge-lentivirus, which contained six tandemly repeated miR-125b binding sites after the stop codon of mCherry coding gene and expressed copGFP, was generated ( Figure 1E ), and its role in reducing miR-125b level was verified in an immortalized HSC cell line, JS1 ( Figure S3 ). The miR-125b-sponge-lentivirus and its control were then intravenously injected into CCl 4 -treated mice at days 5 and 7 after the first administration of CCl 4 ( Figure 1F ). Both immunohistochemical and immunofluorescent analyses showed co-localization of copGFP and a-SMA staining in the fibrous septa area ( Figures S4A and  S4B ), indicating infection of lentiviruses in activated HSCs. Furthermore, compared with the livers from the control group, those from the miR-125b-sponge group displayed a lower level of miR-125b ( Figure S5 ) and much less HSC activation and collagen deposition, as evidenced by reduced a-SMA and Sirius red staining ( Figure 1G ), and decreased hydroxyproline content in the livers ( Figure 1H ), suggesting an alleviation of hepatic fibrosis.
Collectively, these data revealed a promotive role of miR-125b in the development of liver fibrosis.
miR-125b Promotes HSC Activation and Contraction
Next, we used mouse primary HSCs to investigate the effect of miR125b on the activation of HSCs. Primary HSCs were isolated from normal murine livers and then activated by culture for 7 days (Figure 2A) . The activated HSCs displayed a significant increase in the levels of miR-125b ( Figure 2B ) and signature molecules of activated HSCs, such as a-SMA, Col1a1, Col1a2, Timp1, and Fn1 ( Figure 2C ). Of note, inhibition of cellular miR-125b reduced the expression of a-SMA, Col1a1, Col1a2, and Timp1 in the culture-activated HSCs ( Figures 2D and 2E ).
Transforming growth factor b (TGF-b) is a key pro-fibrogenic cytokine that promotes activation of HSCs. 1 Interestingly, TGF-b treatment promoted miR-125b expression ( Figure 3A) , whereas knockdown of TGF-b receptor type I (Tgfbr1), Smad2, or Smad3 (Figure S6A ) significantly reduced the TGF-b-induced miR-125b expression in JS1 cells ( Figure 3B ). As expected, inhibition of miR-125b ( Figure S6B ) abrogated the TGF-b-induced expression of Col1a1, Col1a2 ( Figure 3C ), and a-SMA ( Figure 3D ). Even in the absence of TGF-b, the basal mRNA and protein levels of a-SMA were reduced in the anti-miR-125b-transfected JS1 cells ( Figure 3E ), but enhanced in the miR-125b-overexpressing cells ( Figure 3F ; Figure S6C ). However, inhibition of miR-125b did not change the expression of Col1a1 and Col1a2 in JS1 cells without TGF-b stimulation ( Figure S7 ). Taken together, these data indicate a promoting effect of miR-125b in the activation of HSCs.
It is well known that a-SMA promotes contraction of activated HSCs and consequently increases ECM stiffness. 4, 16 Collagen gel contraction assay was therefore employed to evaluate the contractility of HSCs embedded in collagen matrix. The results showed that the size of gel-containing anti-NC (negative control RNA duplexes)-transfected These data suggest that miR-125b may promote liver fibrosis by enhancing a-SMA expression and HSC contraction.
miR-125b Promotes a-SMA Expression and Enhances HSC Contraction by Directly Targeting Stard13
We then investigated the underlying mechanism responsible for miR125b function. Among the miR-125b targets predicted by TargetScan (http://www.targetscan.org), we focused on Stard13 ( Figure S8 ) because it is a RhoA-specific GTPase-activating protein (GAP) that converts the active GTP-bound RhoA into inactive GDP-bound RhoA. 17, 18 It is known that the active RhoA promotes release of Mrtf-A protein from G-actin in cytoplasm; the resulting free Mrtf-A was then translocated into the nucleus, where it forms a complex with transcriptional factor Srf and activates the transcription of target genes, 19 including a-SMA. We therefore evaluated whether the miR-125b-stimulated a-SMA expression and HSC contraction were dependent on the Stard13-RhoA signaling. As shown, Stard13 protein level was significantly reduced in the culture-activated HSCs (day 7; Figure 5A ), which was inversely correlated with upregulation of miR-125b ( Figure 2B ). In addition, silencing Stard13 by small interference RNA duplexes (siRNAs) in JS1 cells significantly enhanced a-SMA expression ( Figure 5B ) and cell contraction ( Figure 5C ), which phenocopied the effects of miR-125b overexpression ( Figures  3F and 4C) . Moreover, silencing of Stard13 attenuated the suppressive effect of anti-miR-125b on contraction of JS1 cells, suggesting that the fibrosis-promoting effect of miR-125b is carried out through Stard13 ( Figure 5D ). Subsequent dual-luciferase reporter analysis showed that co-expression of miR-125b significantly suppressed the activity of luciferase-containing wild-type, but not mutant, 3
0 UTR of Stard13 ( Figure 5E ; Figure S8 ). Furthermore, overexpression of miR-125b in JS1 cells reduced endogenous Stard13 protein, but not mRNA level, and repression of miR-125b increased the protein level of Stard13 ( Figure 5F ; Figure S9 ). These findings suggest that miR-125b may directly repress Stard13 expression in HSCs.
To further evaluate whether miR-125b affects the activation of RhoA, we determined the level of GTP-bound RhoA by GST-RBD (GSTRho binding domain) pull-down assay. As shown, overexpression of miR-125b or knockdown of Stard13 expression increased the GTP-RhoA level in JS1 cells ( Figure 6A , left panel), whereas inhibition of miR-125b decreased the active RhoA level ( Figure 6A , right panel). Moreover, knockdown of either RhoA ( Figure 6B ) or its downstream factors, Mrtf-A or Srf ( Figure 6C ; Figure S10 ), by RNAi significantly blocked the miR-125b-induced a-SMA expression. Consistently, silencing RhoA also blocked the miR-125b-induced JS1 cell contraction ( Figure 6D ).
Taken together, our findings suggest that expression of miR-125b is increased by TGF-b in activated HSCs, and the increased miR-125b binds to the 3 0 UTR of Stard13 and inhibits its expression, thereby enhancing the RhoA/Mrtf-A/Srf signaling and leading to the increased expression of a-SMA and type I collagen and augmented contraction of HSCs, consequently resulting in hepatic fibrosis (Figure 7 ).
DISCUSSION
In this study, we disclosed a miR-125b-Stard13-RhoA-a-SMA signaling pathway in HSCs and revealed a promotive role of miR125b in HSC activation and liver fibrosis.
miR-125b is a ubiquitously expressed miRNA that plays important roles in cell proliferation, apoptosis, migration, and differentiation. 20 Previous studies have shown that miR-125b is also implicated in different liver diseases, including ALF, 8 non-alcoholic fatty liver disease, 9 cholestasis, 10 and HCC. 11, 12 However, the function and its underlying mechanism of miR-125b in HSC activation and liver fibrosis remain unknown. Here, we disclosed an upregulation of miR-125b in HSCs during hepatic fibrogenesis in vivo ( Figure 1C ) and upon culture activation in vitro ( Figure 2B ). In addition, knockdown of miR-125b suppressed the activation of HSCs in vitro ( Figures  2 and 3) . Moreover, administration of miR-125b-sponge that antagonized endogenous miR-125b alleviated liver fibrosis in CCl 4 -treated mice ( Figures 1G and 1H ). These data suggest a promotive role of miR-125b in HSC activation and liver fibrosis.
Activation of quiescent HSCs is a tightly orchestrated process that includes a number of functional changes, such as increasing proliferation, contractility, and synthesis of ECM components. and miR-335, 24 while other miRNAs, like miR-133 and miR-29, are implicated in hepatic fibrosis by regulating production of ECM components. 25 However, no miRNA has been reported to regulate HSC contraction except miR-126b*. 26 It has been proposed that contractility of activated HSCs may lead to liver stiffness and hepatic sinusoidal vasoconstriction, and eventually cause liver complications, like portal hypertension. 27 Contractile force in activated HSCs is generated by the formation of stress fibers and phosphorylation of myosin light chain (myosin II). 28 RhoA/Rho-kinase signaling plays a critical role in HSC contraction. 29 Previous studies have shown that the expression of a-SMA is upregulated by RhoA/Mrtf-A/Srf signaling in smooth muscle cell, 30, 31 and a-SMA can directly increase the contractility of fibroblasts by incorporating into stress fibers. 4, 5 On the other hand, Rho-kinase increases the phosphorylation of myosin II by inhibiting myosin phosphatase or by promoting phosphorylation of myosin II, thereby enhancing the activity of myosin II and promoting cell contraction. 32 Stard13 is a RhoA-specific GAP that negatively regulates RhoA activation. Here, we showed that miR-125b directly suppressed Stard13 expression and consequently increased the level of active RhoA in HSCs ( Figures 5F and 6A) . Moreover, knockdown of RhoA or its downstream factors, Mrtf-A and Srf, significantly antagonized the miR-125b-induced a-SMA expression ( Figures 6B and 6C) , and inhibition of RhoA expression suppressed the miR-125b-promoted HSC contraction ( Figure 6D ). Furthermore, silencing Stard13 attenuated the suppressive effect of anti-miR-125b on HSC contraction ( Figure 5D ). Therefore, our findings suggest that miR-125b promotes a-SMA expression and cell contraction by targeting the Stard13/RhoA signaling pathway. As shown, inhibition of miR-125b reduced the level of a-SMA in culture-activated primary HSCs ( Figure 2D ) and in JS1 cells with ( Figure 3D ) and without TGF-b treatment ( Figure 3E ). On the other hand, knockdown of miR-125b resulted in a decrease of Col1a1 and Col1a2 in culture-activated primary HSCs ( Figure 2D ) and in TGFb-treated JS1 cells ( Figure 3C ), but not in JS1 cells, without TGF-b treatment ( Figure S7 ). Therefore, we focused on exploring whether miR-125 promoted fibrosis by regulating a-SMA. However, we cannot exclude the possibility that miR-125b may promote liver fibrosis by enhancing Col1a1 and Col1a2 expression.
TGF-b is the most prominent fibrogenic cytokine in HSC activation. It also regulates the expression of several fibrosis-related miRNAs, such as miR-29, 13 miR-133a, 25 and miR-21. 33 Here, we revealed that TGF-b treatment significantly increased the level of miR125b in HSCs. Moreover, knockdown of Tgfbr1, Smad2, or Smad3 blocked the TGF-b-induced miR-125b expression. Notably, inhibition of miR-125b significantly blocked the TGF-b-induced a-SMA expression and HSC contraction. These findings suggest that TGF-b may activate HSCs by increasing miR-125b level during liver fibrogenesis.
At the early phase of CCl 4 treatment, a significant number of fibroblasts undergo proliferation. 34 It is reported that efficient lentiviral transduction in the livers requires cell proliferation in vivo, 35 although it has been shown that lentiviruses can also deliver genes into nondividing cells. 36 This notion is supported by our finding that a number of activated HSCs were successfully infected with lentiviral miR-125-sponge in the CCl 4 -treated fibrosis model ( Figures S4A and S4B ). In addition, infection of miR-125b-sponge-lentiviruses dramatically reduced the miR-125b level in mouse HSCs in vitro ( Figure S3 ) and in CCl 4 -treated livers ( Figure S5 ) in vivo. These findings suggest that miR-125b-sponge-lentiviruses may alleviate liver fibrosis by inactivating HSCs.
In summary, our findings uncover a miR-125b-Stard13-RhoAa-SMA signaling cascade in HSCs and highlight its importance in hepatic fibrosis.
MATERIALS AND METHODS

Human Tissues
Human fibrotic liver tissues were collected from five HCC patients who underwent curative resection at the Cancer Center of Sun Yatsen University and four hepatic failure patients with liver cirrhosis who underwent liver transplantation at the Third Affiliated Hospital of Sun Yat-sen University. The normal liver tissues were collected from nine patients undergoing resection of hepatic hemangiomas at the Cancer Center of Sun Yat-sen University. Informed consent was obtained from each patient, and the study was approved by the Institute Research Ethics Committee. Characteristics of liver fibrosis and hepatic hemangioma patients are shown in Table S1 . 
Mouse Liver Fibrosis Models
Male C57BL/6 mice at 6 weeks of age were purchased from Guangdong Medical Laboratory Animal Center. Two mouse models for liver fibrosis were used in this study. In the model of chemical-induced liver fibrosis, CCl 4 was dissolved in corn oil (1:5, v/v) and intraperitoneally injected into mouse at a dose of 0.5 mL/kg body weight, twice a week for 4 or 6 weeks. Corn oil-injected mice served as controls. In the BDL model, the common bile duct of mouse was ligated for 21 days. Sham-operated mice served as controls. For in vivo viral infection assay, mice were intravenously injected with lentiviruses ($1.6-1.7 Â 10 10 vg resuspended in 100 mL of 1Â PBS). All animal experiment procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals (NIH publications No. 80-23, revised 1996) and according to the institutional ethical guidelines for animal experiments.
Cell Line and Primary Cells
The immortalized mouse HSC line, JS1 37, 38 (kindly gifted by Dr. Jinsheng Guo from Zhongshan Hospital at Fudan University, Shanghai), was maintained in DMEM complemented with 10% fetal bovine serum.
Mouse primary HSCs were isolated from male C57BL/6 mice by collagenase perfusion and density gradient centrifugation as previously described. 39 In brief, liver was perfused sequentially with ethylene glycol-bis (2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA)-containing D-Hank's buffer for 5 min, then with 0.25 mg/mL collagenase I-containing Hank's buffer for 20 min. The perfused liver was transferred to a beaker, minced, and digested with 0.02 mg/mL DNase I-containing Hank's buffer for 10 min at 37 C with slowly stirring. The resulting cell homogenates were filtered through a 100-mm cell strainer followed by washing twice www.moleculartherapy.org with ice-cold Hank's buffer. Cell pellets were re-suspended in 15% OptiPrep (Alere Technologies, Norway) and topped with 11.5% OptiPrep and then with 1Â PBS. After centrifuging at 1,400 Â g, 4 C for 17 min, the viable HSCs between layers of 11.5% OptiPrep and 1Â PBS were collected and then washed once with ice-cold 1Â PBS. The purity of the isolated HSCs was assessed by retinoid autofluorescence. HSCs with purity over 90% were used.
To isolate primary hepatocytes, we washed cell homogenates with icecold Hank's, then re-suspended in 50% Percoll (diluted by Hank's buffer; GE Healthcare, Chicago, IL, USA) and centrifuged at 50 Â g, 4 C for 15 min. The isolated hepatocytes were washed with ice-cold Hank's buffer. Both primary HSCs and hepatocytes were cultured in DMEM supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin.
RNA Oligoribonucleotides and Vectors
miR-125b mimic, siRNAs, negative control RNA duplexes (NC), and the sequence-specific RNA oligoribonucleotide of miR-125b inhibitor (anti-miR-125b) and its control (anti-NC) with 2 0 -O-methyl modification were purchased from Genepharma (Shanghai, China). Sequences of all RNA oligoes used in this study are listed in Table S2 .
For vectors, a psiCHECK-2 (cat. C8021; Promega, Madison, WI, USA) vector was used to construct luciferase reporter plasmids, including psiCHECK2-Stard13-3 0 UTR-WT and psiCHECK2-Stard13-3 0 UTR-MUT, which contained a wild-type and mutant 3 0 UTR segment of mouse Stard13 gene, respectively.
A lentiviral vector with miR-125b-sponge, which contained six tandem repeats of miR-125b binding sequence following the stop codon of mCherry gene, was used. The fused mCherry-miR-125b-sponge sequence was PCR amplified from ED214 plasmid 40 (kindly gifted by Dr. Dieter Edbauer from the Picower Institute for Learning and Memory, USA) and inserted into the multiple cloning sites of pCDH-CMV-MCS-EF1-copGFP vector (cat. CD511B-1; System Biosciences, Palo Alto, CA, USA). A control vector (Ctrl) that only contained mCherry expression cassette without miR-125b binding sequence was also generated.
Sequences of all primers used for plasmids construction are listed in Table S2 . Packaging of the lentiviruses for miR-125b-sponge expression was performed in HEK293T cells by calcium phosphate transfection.
Cell Contraction Assay JS1 (4 Â 10 4 cells) were mixed with rat-tail collagen (final concentration 1 mg/mL), incubated for 1 hr at 37 C in a 48-well plate to allow gelation, and then maintained in 10% FBS-containing DMEM for 24 hr. To initiate contraction, we detached the gel lattice from the cell culture plate and incubated for another 24 or 48 hr before staining with crystal violet. The radius (r) of collagen gel was measured, and the area (S) was calculated using the formula: S = p Â r 2 . The contraction area was defined as the reduced collagen gel surface area after collagen lattice release. The mean value of contraction areas from multiple independent experiments in the control group was set to 1. Relative contraction area is presented.
RhoA Activation Assay
Recombinant GST-RBD fusion proteins were purified from Escherichia coli that had been transformed with pGEX-2T-GST-RBD plasmid and immobilized on glutathione-Sepharose 4B beads (cat. C600031; Sangon Biotech, Shanghai, China), as described previously. 41 For the GST pull-down assay, JS1 cells were washed once with ice-cold 1Â PBS and lysed on ice using eukaryotic cell lysis buffer (25 mM HEPES [pH 7.5], 150 mM NaCl, 1% NP-40, 10 mM MgCl 2 , 1 mM EDTA, 2% glycerol) supplemented with protease inhibitors. The cell lysates were then incubated with immobilized GST-RBD for 2 hr at 4 C. The bead-immunocomplexes were washed three times with eukaryotic cell lysis buffer, and the bead-bound proteins were eluted with SDS buffer and analyzed by immunoblotting.
Hydroxyproline Assay
Collagen deposition of the liver was quantified by determining hydroxyproline content using the Hydroxyproline Colorimetric Assay Kit (cat. K555-100; BioVision, Milpitas, CA, USA). In brief, frozen liver tissues were hydrolyzed with 6 N HCl at 120 C for 3 hr. After brief cooling on ice and centrifugation at 10,000 Â g for 3 min, 10 mL of the supernatant was transferred to a 96-well plate and incubated at 80 C until complete desiccation. Then 100 mL chloramine T reagent was added to each sample and incubated at room temperature for 5 min, followed by adding 100 mL of 4-dimethylaminobenzaldehyde (DMAB) reagent and incubation at 60 C for 90 min. After cooling to room temperature, absorbance at 560 nm was measured in a microplate reader (Infinite M200 Plate Reader; Tecan, Männedorf, Switzerland). Hydroxyproline content was expressed as micrograms per gram (mg/g) of liver tissue.
Statistical Analysis
The data are expressed as the mean ± SEM from at least three independent experiments. The differences between the groups were analyzed using Student's t test when two groups were compared or by one-way ANOVA when more than two groups were compared.
Analyses were performed using the GraphPad Prism program (version 6.0; GraphPad Software, San Diego, CA, USA). All statistical tests were two-sided, and p < 0.05 was considered to be statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes ten figures and two tables and can be found with this article online at https://doi.org/10.1016/j.omtn. 2018.04.016. 
AUTHOR CONTRIBUTIONS
CONFLICTS OF INTEREST
No conflicts of interest were declared.
